3SBio Acquires Wansheng To Bolster Small Molecule Portfolio
This article was originally published in PharmAsia News
China’s 3SBio has been actively scouting M&A targets in both overseas and domestic markets, aiming to enrich its product pipeline and diversify its offering. It has now landed its first acquisition, of a chemical drug maker in China, just one month after its Hong Kong IPO, in a deal that will provide 3SBio with an integrated small molecule R&D and manufacturing platform and increase its manufacturing cost competitiveness.
You may also be interested in...
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.